ClinicalTrials.gg
CompletedNCT05512806Updated Nov 9, 2023

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

A Phase 1 interventional study of AZD5462 in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the pharmacokinetics of AZD5462 film-coated tablet formulation in healthy participants.

Read the detailed description

This study will consist of six treatment periods.

A total of 16 healthy male and female participants of non-childbearing potential will be randomized in this study to ensure at least 12 evaluable participants at the end of the last treatment period.

The study will comprise of a Screening Period, six Treatment Periods, and a follow-up phone call:

  • A screening period of maximum 28 days.
  • Six treatment periods during which participants will be residents at the study center from Day -1 until Day 17.

Each participant will receive 6 treatments.

The following treatments will be given:-

  • Treatment A: Dose A of AZD5462 film-coated tablet in a fasted state.
  • Treatment B: Dose A of AZD5462 film-coated tablet in a fed state.
  • Treatment C: Dose B of AZD5462 film-coated tablet in a fasted state.
  • Treatment D: Dose B of AZD5462 oral solution in a fasted state.
  • Treatment E: Dose C of AZD5462 film-coated tablet in a fasted state.
  • Treatment F: Dose C of AZD5462 film-coated tablet in a fed state.
  • A follow-up phone call will take place on Day 21 (± 1 day) to record adverse events (AEs) and concomitant medication.
02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy participants
  • Food effect
  • Relative bioavailability
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures.
  • Healthy male and female participants aged 18 to 55 years at screening and admission with suitable veins for cannulation or repeated venipuncture.
  • Females must have a negative pregnancy test at screening and on admission to the study center, must not be lactating and must be of non- confirmed at screening by fulfilling one of the following criteria:

    1. defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and Follicle-stimulating hormone (FSH)/Luteinizing hormone (LH) levels in the postmenopausal range.
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  • Male participant must adhere to the methods details.
  • Have a (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 105 kg inclusive at screening.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • Any of the below conditions:

    1. Systemic sclerosis.
    2. Moderate to severe valvular disease.
    3. Hypertrophic obstructive cardiomyopathy.
    4. Restrictive cardiomyopathy.
    5. Gilbert's syndrome.
    6. History of vascular or left ventricular aneurysms, or prior dissections.
    7. Any history of joint hypermobility, Marfan's Syndrome, or any connective tissue disorder.
  • History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of medicinal product (IMP).
  • Any laboratory values with the following deviations at screening, or admission to the study center:

    1. Total > (ULN).
    2. > 1.5 × ULN.
    3. Aspartate aminotransferase > 1.5 × ULN.
    4. Estimated (eGFR) \< 90 mL/min/1.73m2, as assessed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
    5. White blood cell count \< 3.5 k/uL and > ULN.
    6. \< Lower limit of normal (LLN).
  • Any clinically significant abnormalities in clinical biochemistry, hematology, or urinalysis results.
  • Any clinically significant abnormal findings in vital signs after 5 minutes supine rest, at screening or admission defined as any of the following:

    1. Systolic Blood pressure (BP) \< 90 mmHg or ≥ 140 mmHg.
    2. Diastolic BP \< 50 mmHg or ≥ 90 mmHg.
    3. Heart rate \< 50 bpm or > 90 bpm.
  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting 12-lead (ECG) at screening or admission.

    1. Prolonged > 450 ms.
    2. Shortened QTcF \< 340 ms.
    3. Family history of long QT syndrome.
    4. PR(PQ) interval shortening \< 120 ms (PR > 110 ms but \< 120 ms is acceptable if there is no evidence of ventricular pre-excitation).
    5. PR(PQ) interval prolongation (> 240 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third-degree AV block, or AV dissociation.
    6. Persistent or intermittent complete BBB. Participants with Intraventricular conduction delay (IVCD) with QRS \< 120 ms are acceptable if there is no evidence of eg, ventricular hypertrophy, or pre-excitation.
  • Any positive result on screening for serum surface antigen, antibody, and (HIV) antibody.
  • Known or suspected history of drug abuse.
  • Has received another new chemical entity within 30 days of the first administration of IMP in this study.
  • Plasma donation within 1 month of screening or any blood donation/loss > 500 mL during the 3 months prior to screening.
  • History of severe allergy/ or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD5462.
  • Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.
  • Positive screen for drugs of abuse, alcohol, or cotinine at screening or on each admission to the study center prior to the first administration of the IMP.
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
  • Use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, megadose vitamins, and minerals during the 2 weeks or 5 half-lives of the medication, whichever is longer, prior to the first administration of IMP.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  • Excessive intake of caffeine-containing drinks or food.
  • Participants who have previously received AZD5462.
  • Any ongoing or recent minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Participants who are vegans or have medical dietary restrictions.
  • Participants who cannot communicate reliably with the Principal Investigator (PI).
  • Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  • Clinical signs and symptoms consistent with Coronavirus disease 2019 (COVID-19), or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment A

    Participants will receive Dose A orally as a film-coated tablet.

    Drug: AZD5462

  • Experimental
    Treatment B

    Participants will receive Dose A orally as a film-coated tablet.

    Drug: AZD5462

  • Experimental
    Treatment C

    Participants will receive Dose B orally as a film-coated tablet.

    Drug: AZD5462

  • Experimental
    Treatment D

    Participants will receive Dose B orally as an oral solution.

    Drug: AZD5462

  • Experimental
    Treatment E

    Participants will receive Dose C orally as a film-coated tablet.

    Drug: AZD5462

  • Experimental
    Treatment F

    Participants will receive Dose C orally as a film-coated tablet.

    Drug: AZD5462

Interventions

  • Participants will receive AZD5462 orally.

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration time curve from zero to infinity (AUCinf)

    The AUCinf of a film-coated tablet of AZD5462 at 3 dose levels will be assessed.

    Time frame: Day 1 to Day 17

  2. Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)

    The AUClast of a film-coated tablet of AZD5462 at 3 dose levels will be assessed.

    Time frame: Day 1 to Day 17

  3. Maximum observed plasma (peak) drug concentration [Cmax]

    The Cmax of a film-coated tablet of AZD5462 at 3 dose levels will be assessed.

    Time frame: Day 1 to Day 17

  4. Area under plasma concentration time curve from zero to infinity (AUCinf)

    The effect of a high-fat, high-calorie meal in comparison to fasting conditions on the AUCinf of AZD5462 after a single oral dose at 2 dose levels will be assessed.

    Time frame: Day 1 to Day 17

  5. Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)

    The effect of a high-fat, high-calorie meal in comparison to fasting conditions on the AUClast of AZD5462 after a single oral dose at 2 dose levels will be assessed.

    Time frame: Day 1 to Day 17

  6. Maximum observed plasma (peak) drug concentration [Cmax]

    The effect of a high-fat, high-calorie meal in comparison to fasting conditions on the Cmax of AZD5462 after a single oral dose at 2 dose levels will be assessed.

    Time frame: Day 1 to Day 17

  7. Area under plasma concentration time curve from zero to infinity (AUCinf)

    The relative bioavailability of the film-coated tablet vs oral solution formulation will be determined by the assessment of AUCinf.

    Time frame: Day 1 to Day 17

  8. Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)

    The relative bioavailability of the film-coated tablet vs oral solution formulation will be determined by the assessment of AUClast.

    Time frame: Day 1 to Day 17

  9. Maximum observed plasma (peak) drug concentration [Cmax]

    The relative bioavailability of the film-coated tablet vs oral solution formulation will be determined by the assessment of Cmax.

    Time frame: Day 1 to Day 17

Secondary outcomes

  1. Number of participants with Adverse Events (AEs), and Serious Adverse Events (SAEs)

    The safety, and tolerability of single doses of AZD5462 in healthy participants will be assessed.

    Time frame: Until follow-up (Day 21)

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Nov 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 23, 2022
StartActual
Aug 24, 2022
Primary completionActual
Nov 7, 2022
CompletionActual
Nov 7, 2022
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05512806
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Aug 23, 2022
Start date
Aug 24, 2022
Primary completion
Nov 7, 2022
Completion
Nov 7, 2022
Last update
Nov 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pexerelgon

Start the discussion